Accordingly, considering of the Fyn/Tim-3 and Bat3/Tim-3 axes could be a promising molecular target for therapeutic interventions in hematological malignancies like CLL. The gene discussed is HAVCR2; the disease is B-cell chronic lymphocytic leukemia.